

Registered number: 02631049  
Charity number: 1003904

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART  
UK)**  
**(A company limited by guarantee)**

**Trustees' report and financial statements**  
**for the year ended 28 February 2017**

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Contents**

---

	Page
<b>Reference and administrative details of the charity, its trustees and advisers</b>	1
<b>Trustees' report</b>	2 - 10
<b>Independent auditors' report</b>	11 - 12
<b>Consolidated statement of financial activities</b>	13
<b>Consolidated balance sheet</b>	14
<b>Charity balance sheet</b>	15
<b>Consolidated cash flow statement</b>	16
<b>Notes to the financial statements</b>	17 - 30

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Reference and administrative details of the charity, its trustees and advisers  
for the year ended 28 February 2017**

---

**Trustees**

Mr R Edwards FCA, Chairman  
Professor E A Hughes, Trustee  
Professor J D Reckless, Trustee  
Ms G Howells, Trustee  
Mr M Crozier, Trustee (resigned 23 March 2017)  
Mr S D Boley ACA, Trustee  
Dr D Neely, Trustee  
Ms T Ghosh, Trustee  
Dr A Rees, Trustee  
Ms J Bennett, Trustee  
Ms Z A Merchant, Trustee  
Dr R Cramb, Trustee  
Ms T Kennerley, Trustee

**Company registered number**

02631049

**Charity registered number**

1003904

**Registered office**

7 North Road, Maidenhead, Berkshire, SL6 1PE

**Company secretary**

Ms J Payne

**Chief executive officer**

Ms J Payne

**Independent auditors**

Haines Watts, Sterling House, 177-181 Farnham Road, Slough, Berkshire, SL1 4XP

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Trustees' report**  
**for the year ended 28 February 2017**

---

The Trustees present their annual report together with the audited financial statements of for the year 1 March 2016 to 28 February 2017.

**Operating and Financial review**

It has been an incredible year for HEART UK. Abnormal levels of Cholesterol are at last returning as a concern at senior decision making levels within Government and the NHS. Early identification of familial hypercholesterolaemia (FH) is receiving much more attention. Our successful influence on the decision making process follows pressure from HEART UK on ministers, members of parliament and senior civil servants within the NHS and we continue to exert such influence.

We are helping ever more people with an increasing wealth of information to manage their high cholesterol levels. HEART UK is uniquely placed, as the experts in cholesterol to provide support to both health care professionals and members of the public. The information we provide is based only towards what is factually accurate and scientifically grounded as more and more people rely on HEART UK as the primary source of knowledge on cholesterol.

As the spotlight shines more on cholesterol so too does the demand for our services. It is important that we can keep up with this demand and manage it as best we can with investments in our infrastructure. Through careful examination of many of our activities we have been able to maintain a high level of service while at the same time generating savings. These savings have provided us with a surplus to invest.

To help us support and help more people we are able to invest in the helpline. The helpline is much more than a vital telephone service able to offer expertise from cardiac nurses and dietitians but is a lifeline to those that need to change their diet and lifestyle in order to lower their cholesterol.

We are also able to make additional investment in our longer term sustainability through developing more relationships in the corporate sector. These new relationships will form vital income generation in the years ahead and make significant contributions towards expanding our resources to meet demand and serving those in need.

We are also pleased to report that no less than 85% of our income is related to delivering our charitable objectives.

**Thanks to our team**

Thanks to our staff who have worked with enthusiasm and commitment throughout the year. Their efforts have been the foundation of all that the charity has achieved during the year.

**Thanks to our volunteers**

We rely heavily on the generous donation of time and enthusiasm of more than 100 volunteers to help us achieve our objectives. Volunteers bring with them expertise as health care professionals and also those directly affected by high cholesterol. Their collective knowledge and experience is a significant contribution towards the expertise that HEART UK provides through our support, education and influence.

**Thanks to our fundraisers**

Fundraisers are our heroes and run marathons, organise sponsored events and give money towards our services to help others. From the London Marathon to the Great Cholesterol Challenges, the sweat and effort of these amazing fundraisers is greatly appreciated.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Trustees' report (continued)**  
**for the year ended 28 February 2017**

---

### **Supporting**

HEART UK remains a trusted and reliable source of accurate and unbiased facts. For many people the internet is the primary source of information and our website includes a wealth of knowledge for health care professionals and the public. The HEART UK website includes advice on diet, lifestyle and medication to lower cholesterol in addition to expertise on many blood fat conditions. The HEART UK website is used over 2 million times a year and we continue to develop additional ways to share our work with more people. Social media plays an ever increasing part of many people's lives and we need to keep pace and engage people in this changing environment. Through channels such as Twitter we are able to reach a wide audience with our messages to either offer advice or to ask for support, which helps increase awareness of HEART UK and the importance of knowing more about cholesterol.

We also continue to rely on our factsheets and booklets which are posted out in their thousands all over the country. From GP practices to local authorities, community pharmacists to local gyms our written materials are made available free of charge. While it is essential to expand into new and exciting ways of sharing our work online, it is similarly essential that we continue to use traditional print too.

HEART UK continues to feature in newspapers, magazines and journals in addition to the radio and appearances on the TV. HEART UK provides the factual and accurate element to a media story and often provides considerable background knowledge for journalists and reporters. We have received a good amount of coverage and recognition. This public relations role is now provided internally at HEART UK and we deal directly with the media to provide first hand assistance.

We have set up an FH Intelligence Network, which is a monthly telephone conference during an evening for health care professionals, providers and commissioners of FH service. The call is an opportunity to help share good practice and identify solutions to any issues that need addressing. The conference call is free to callers and an ideal supporting network for FH services.

We have been driving forward having one FH Register, which is working very well with now over 6,000 FH patients on the FH Register who have been genetically diagnosed with FH. This system is a pedigree system so it can share information around hospital Trusts, with the correct patient consents in place of course. This is already showing a huge benefit for the Trusts that have access to this FH Register, both in terms of the sharing of information and the benefit on time and of course they are already seeing savings too. We were aware that each Trust were operating on their own so HEART UK set about pulling together an FH Registry Advisory Group, which is now set up with representation from across the UK including Lipidologists, FH nurses and paediatricians. This group will be overseeing the FH Registry and all the Governance issues that go along with this.

### **Important programmes**

Our Ambassador programme is very important to us as these individuals represent HEART UK in their community and they help to spread our messages far and wide, raising much needed awareness of the organisation and our services but also getting people to think about their own health and that of their families.

To further support families, in particular children and young people, HEART UK is developing an exciting and ambitious new programme. The Children and Young People Programme (CYPP) will cover all blood conditions but we are focusing on FH first. The programme includes three important elements to help children and young people better understand and manage FH. HEART UK held focus groups with children and young people at a Family Day event which highlighted the needs for tailored support for younger ages. With the expert advice from a paediatrician, genetic councillor, adult patient and dietitian and an FH nurse we are developing a series of information booklets written for different ages spanning primary, junior and secondary schools.

Appropriately aged children and young people review the materials for us and will steer the programme through

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Trustees' report (continued)**  
**for the year ended 28 February 2017**

---

the FH Advisory Board (FHAB).

Materials will be available online too and our intention is to provide a dedicated web space for children and young people to access information written specifically for them.

The two further elements to the programme include a peer support network, whereby younger ages will be able to share their experiences of living with FH to help minimise the feeling of loneliness and of feeling different to other children, together with a series of family events where families can get together and talk through practical and every-day-issues they face.

### **FH Europe**

With European partners, we have developed FH Europe. This is a European FH Patient Network and has over 20 countries involved, both EU and non EU. The organisation is a standalone charity (Charity number 1170731). The network shares best practice, attends health care professional conferences raising awareness of the FH patient group organisations in each country, holds a face to face meeting once a year providing a networking opportunity as well as education and sharing information. FH Europe has also launched their Call to Action setting out priorities for the European Parliament and local country MEPs to prioritise and raise awareness of FH as a genetic cause of CVD. They have developed a brochure and set up a social media following and their focus in the coming year is to set up a new website, continue with their e-flash providing regular updates from around Europe and also to hold the face to face meeting in Budapest in November 2017. They have appointed a part time administrator and HEART UK is the administrative centre.

### **Educating**

We celebrated our 30th anniversary of holding an annual scientific conference. We held the conference in Edinburgh with the majority of our founders attending and speaking at the launch. We are extremely proud to be held in such high regard for such a great group of people that come to conference to continue to learn and network together for the benefit of the patient.

HEART UK published a paper on our 'Statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom'. This sets out how patients with such a severe form of FH should be treated as best practice.

We have held a number of patient meetings during the year and plan on doing more of this work in the coming year as patients find them incredibly helpful.

We have launched our LearningZone, where we are hosting all our learning materials for health care professionals. We plan to focus on this in the coming year to build further training.

Grants are an important part of the science, since we have launched the HEART UK grant scheme we have supported two projects, one focused on working with children and young people to develop an FH e-learning supplement for paediatricians and another on improving definition and diagnosis of Familial Combined Hyperlipidaemia. An update on the latter will be presented at the HEART UK conference in July 2017.

### **Influencing**

We continue to influence health policy on all local and national levels by engaging with key opinion leaders on a range of lipid subjects.

HEART UK plays a pivotal role on important key decision making bodies, such as:

- NHS England's FH Steering Group chaired by the National Clinical Director for Cardiovascular Disease, Prof. Huon Gray. That group is driving forward FH Services;
- CVD Collaboration Group bringing together a range of individuals and organisations to look at CVD,

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

---

**Trustees' report (continued)**  
**for the year ended 28 February 2017**

---

- including cholesterol and how they can work together to achieve CVD being a focus for the NHS; and the National Cardiovascular Intelligence Network which is a group looking at using data to demonstrate improvements, or otherwise, for CVD. This is a big challenge as cholesterol is not routinely recorded by more than 40% of primary care clinicians.

FH has now been accepted and will be included within the NHS strategy for personalised medicine, the group working on this strategy are working closely with the 100,000 Genome project group.

We have been involved with raising awareness of the importance of NHS Health Checks and work closely with Public Health England and actively contribute to the collaborative group too to make sure as many people are accessing these services in order to identify an early problem.

We were delighted when Prof. David Wald published his paper 'Child-Parent Familial Hypercholesterolemia Screening in Primary Care'. The study tested the cholesterol levels in primary care of 10,000 babies, between the age of 1 – 2. This led to FH being identified much earlier in age. Sadly the National Screening Committee (NSC) had published their decision not to consider FH as an early screening programme; but this study changes things. We have managed to influence the NSC to reconsider their position. As at the time of writing this, we await a decision. This would make a huge difference to families and FH being identified much earlier, therefore earlier treatment and less development of CVD or avoidance of death.

A sensitive area of our work has been that around Death Certificates. We know of tragic experiences from families calling our helpline of unexpected deaths from young people, including young children and babies. The Death Certificates rarely include an underlying reason of death when, for example myocardial infarction (heart attack) is the cause. We believe families need to know that there may be an inherited condition such as FH they need to be tested for, so that they can seek appropriate treatment. We have met with the Royal College of Pathologists and will work with coroners, medical examiners and others to raise awareness of FH and other lipid conditions that can bring about an early and tragic death.

We have fed into a range of Government consultations during the year, including the NICE FH Guidelines which will be published mid 2017. We continue to benefit from the world class expertise of the HEART UK Medical Scientific and Research Committee who advise on consultations and official Government responses.

#### **Changes to Fundraising and Data Protection Regulations**

The new Fundraising Regulations are yet to be published, we are expecting these to be launched around the Summer 2017. There has been a consultation on certain aspects of the changes and we have fed into this process. We believe HEART UK is already adopting the approach that will be set out by the Fundraising Regulator.

With regard to Data Protection, there has been much coverage over a number of large charities that have received fines by the Information Commissioner. This is a complex subject and the changes are extremely complicated and time consuming to understand. There is currently no clear guidance on the matter. In fact, the changes being introduced in May 2018 will be required by all organisations, not just charities. However, charities are being encouraged to go beyond the law and to do so before the law is introduced. We very much welcome this approach. We certainly do not carry out any of the activities that the large charities were fined for. We communicate with people who would like us to keep in touch with them. As all other charities, we do have some tweaking to do to our systems, but we are keen to resolve this quickly. Clearly this can be an onerous task on a small charity, but we welcome the change with open arms as we want to be talking to those who are interested in our work.

The Trustees are kept fully informed about the developments and the subject is discussed at each Board meeting.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Trustees' report (continued)**  
**for the year ended 28 February 2017**

---

**Objectives and Activities**

**a. Policies and objectives**

The principal objects of the Charity are:

- To relieve those suffering the effects of heart disease and in particular lipid disorders, familial hyperlipidaemias and related conditions
- To promote the relief of sickness and the preservation and protection of health by reducing the incidence of cardiovascular disease in the general population of the UK;
- To provide counselling and advice to relatives of those diagnosed with inherited heart disease;
- To promote the study of causes, diagnosis and treatment of lipid disorders and associated metabolic diseases.
- The subsidiary company objects are to support the charity through the sale of publications and other such commercial activities.

**Financial review**

**a. Going concern**

After making appropriate enquiries, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

See the Operating and Financial Review for information about all our activities.

**b. Reserves policy**

The trustees have decided that we should hold at least 6 months and ideally 9 months reserves to ensure the orderly running of the charity in the event of a funding crisis. We currently are exceeding our minimum and hold 81% of our ideal reserve level.

**c. Investments policy**

Under the Memorandum and Articles of Association, the charity has the power to invest in any way the Trustees see fit.

**Structure, governance and management**

**a. Constitution**

The charity is constituted as a charitable company limited by guarantee and is governed by its Memorandum and Articles of Association. It is registered with The Charities Commission (number 1003904) under the Charities Act.

Overall responsibility rests with the Board of Trustees who are also appointed as Directors of the charitable company. The Trustees meet formally four times a year. In addition, the Trustees hold an annual 'away day' when the future strategy of the charity is discussed.



---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

---

**Trustees' report (continued)**  
**for the year ended 28 February 2017**

---

**b. Method of appointment or election of Trustees**

Trustees are appointed in accordance with the Articles of Association, including receipt and approval of an application for legal membership.

New Trustees are briefed on their legal obligations under charity and company law, the content of the Memorandum and Articles of Association, the business plan and recent financial performance of the Charity.

During the induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role.

**c. Organisational structure and decision making**

Authority from the Trustees is delegated to the Chief Executive, who is responsible for the day-to-day running of the charity.

**d. Related party relationships**

A number of Committees and Working Groups operate to assist in the delivery of our objectives and report directly to the Trustees, these are:

**The Medical and Scientific Research Committee (MS&R)**

Oversees the Annual Conference, the development of research and speciality training programmes, allocation of research awards and clinical guidelines development and updating of factsheets.

The following sub-committees and working groups report to the MS&R:

**The Laboratory Scientific Sub-Committee (meets on a needs basis)**

The key areas of interest are:

- The accuracy of lipid measurement in UK pathology laboratories.
- To define core laboratory investigations for Lipid Clinic assessment of patients with dyslipidaemia. To develop standards for lipid analysis and reporting.
- To promote the highest standards in point of care testing for cholesterol measurement.
- To help complete pathways for specialist lipid analysis, including research on difficult/unusual patients.

**The Simon Broome Register Scientific Sub-Committee**

Is responsible for directing research based on a national cohort of over 3,500 patients with familial hypercholesterolaemia (and severe hypertriglyceridaemia).

**Lipoprotein Apheresis Working Group**

The key areas of interest are:

- To promulgate guidance for the clinical indication for lipoprotein apheresis.
- To review and recommend the criteria of efficacy of performance in the UK (Assessment to be based on Registry data jointly formed by HEART UK and the Royal College of Physicians).
- To educate society in general about Apheresis as a treatment.

**The Health Care Committee**

The key areas of interest are:

- Provides up-to-date information to health care professionals who care for patients and their families with lipid disorders.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Trustees' report (continued)**  
**for the year ended 28 February 2017**

---

- They co-organise the Health Care and Patient part of the Annual Conference.

**The Patients and Supporters Committee**

The key areas of interest are:

- To represent the interests and needs of patients with cholesterol (lipid) conditions.
- To oversee: Communications

**The Income Generation Sub-Committee**

The key areas of interest are:

- To oversee the fundraising activities of the organisation, including from non food and pharmaceutical corporate relationships.

**The Campaigning Committee**

The key areas of interest are:

- To position cardiovascular disease (CVD) as the Government's a top public health priority, with cholesterol acknowledged as a key risk factor for CVD; increase levels of lipids and cholesterol testing.
- To ensure there are clearly understood range of solutions to managing cholesterol for both health care professionals and the public.

**The Finance and Risk Committee**

The key focus of this committee is to be responsible for financial and general business affairs of the charity including:

- Risk Management
- Financial Control Management
- Audit and presenting final accounts to the AGM following Board approval.
- Reviewing annual accounts prior to Board and then AGM approval.

**Product Approval Working Group**

For approved commercial products that bear the HEART UK logo. The group operates within an ethical and scientific policy framework to evaluate products for approval.

**Lipid Interest Group**

Is a networking group for health care professionals either working in lipids or with an interest in lipids.

**Policy Development Group**

Operates to develop, oversee and review the policies of the organisation.

**FH Registry Advisory Group**

This group oversees the Governance of the FH Registry.

**e. Risk management**

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the charity, and are satisfied that systems and procedures are in place to mitigate our exposure to the major risks.

The Trustees accept their responsibilities in the management of risk and have a risk management strategy which comprises:

- A quarterly review of the risks the Charity faces.
- The creation of internal controls, systems and procedures to mitigate those risks identified in the review.
- The implementation of procedures designed to minimise any potential impact on the Charity should those risks materialise.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Trustees' report (continued)**  
**for the year ended 28 February 2017**

---

In addition to these formal reviews there are ongoing operational management decisions that make adjustments and amendments as and when risks are identified in everyday operations.

**Trustees' responsibilities statement**

The Trustees (who are also directors of Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK) for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable group for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable group will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company and the group's transactions and disclose with reasonable accuracy at any time the financial position of the charitable group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable group's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**Disclosure of information to auditors**

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable group's auditors are unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable group's auditors are aware of that information.

---

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)  
(A company limited by guarantee)

---

Trustees' report (continued)  
for the year ended 28 February 2017


---

**Auditors**

The auditors, Haines Watts, have indicated their willingness to continue in office. The Designated Trustees will propose a motion re-appointing the auditors at a meeting of the Trustees.

This report was approved by the Trustees on 6 July 17 and signed on their behalf by:

  
.....  
Mr R Edwards FCA, Chairman

  
.....  
Mr S D Boley ACA, Treasurer

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Independent auditors' report to the members of Hyperlipidaemia Education & Atherosclerosis  
Research Trust UK (HEART UK)**

---

We have audited the financial statements of Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK) for the year ended 28 February 2017 which comprise the group Statement of financial activities, the group and charity Balance sheets, the group Cash flow statement and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, section 151 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinion we have formed.

**Respective responsibilities of Trustees and auditors**

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charity for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditors under the Companies Act 2006 and section 151 of the Charities Act 2011 and report to you in accordance with those Acts. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

**Scope of the audit of the financial statements**

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the group's and the parent charity's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the Trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustees' report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

**Opinion on financial statements**

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 28 February 2017 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

---

**Independent auditors' report to the members of Hyperlipidaemia Education & Atherosclerosis  
Research Trust UK (HEART UK)**

---

**Opinion on other matter prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit, the information given in the Trustees' Annual report for the financial year for which the financial statements are prepared is consistent with those financial statements and such reports have been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of our knowledge and understanding of the group and the parent charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustee's Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Act 2011 requires us to report to you if, in our opinion:

- the parent charity has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charity financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to take advantage of the small companies' exemption from the requirement to prepare a Group strategic report.

*Jonathan Moughton*

Jonathan Moughton (Senior statutory auditor)

for and on behalf of

**Haines Watts**

Statutory Auditors and Chartered Accountants

Sterling House  
177-181 Farnham Road  
Slough  
Berkshire  
SL1 4XP

Date: *21 July 2017*

Haines Watts are eligible to act as auditors in terms of section 1212 of the Companies Act 2006.

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

**Consolidated statement of financial activities incorporating income and expenditure account  
for the year ended 28 February 2017**

	Note	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
<b>Income from:</b>					
Donations and legacies	2	159,716	-	159,716	222,479
Charitable activities	3	150,458	-	150,458	111,394
Trading income	4	752,601	-	752,601	433,337
Other income	5	110,985	-	110,985	21,583
Investment income	6	3,800	-	3,800	4,262
<b>Total income</b>		<b>1,177,560</b>	<b>-</b>	<b>1,177,560</b>	<b>793,055</b>
<b>Expenditure on:</b>					
Raising funds	7	85,649	-	85,649	114,154
Trading costs	8	422,755	-	422,755	315,744
Charitable activities	9	493,206	-	493,206	389,173
Governance	10	8,000	-	8,000	7,260
<b>Total expenditure</b>		<b>1,009,610</b>	<b>-</b>	<b>1,009,610</b>	<b>826,331</b>
<b>Net income / (expenditure) before investment gains/(losses)</b>		<b>167,950</b>	<b>-</b>	<b>167,950</b>	<b>(33,276)</b>
Net gains/(losses) on investments	14	1,662	-	1,662	(1,354)
<b>Net income / (expenditure) before other recognised gains and losses</b>		<b>169,612</b>	<b>-</b>	<b>169,612</b>	<b>(34,630)</b>
<b>Net movement in funds</b>		<b>169,612</b>	<b>-</b>	<b>169,612</b>	<b>(34,630)</b>
<b>Reconciliation of funds:</b>					
Total funds brought forward		292,578	5,242	297,820	332,450
<b>Total funds carried forward</b>		<b>462,190</b>	<b>5,242</b>	<b>467,432</b>	<b>297,820</b>

All activities relate to continuing operations.

The notes on pages 17 to 30 form part of these financial statements.


**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**  
**Registered number: 02631049**

**Consolidated balance sheet**  
**as at 28 February 2017**

	Note	28 February 2017 £	29 February 2016 £
<b>Fixed assets</b>			
Tangible assets	13	15,166	18,327
Investments	14	15,219	13,557
		30,385	31,884
<b>Current assets</b>			
Debtors	15	290,685	230,761
Cash at bank and in hand		770,777	610,149
		1,061,462	840,910
<b>Creditors:</b> amounts falling due within one year	16	(624,415)	(574,974)
<b>Net current assets</b>		437,047	265,936
<b>Net assets</b>		467,432	297,820
<b>Charity Funds</b>			
Restricted funds	17	5,242	5,242
Unrestricted funds	17	462,190	292,578
<b>Total funds</b>		467,432	297,820

The financial statements were approved by the Trustees on *6 July 2017* and signed on their behalf, by:

  
 .....  
 Mr R Edwards FCA, Chairman

  
 .....  
 Mr S D Boley ACA, Treasurer

The notes on pages 17 to 30 form part of these financial statements.




**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**  
**Registered number: 02631049**

**Charity balance sheet**  
**as at 28 February 2017**

	Note	28 February 2017 £	29 February 2016 £
<b>Fixed assets</b>			
Tangible assets	13	15,166	18,327
Investments	14	15,221	13,559
		<b>30,387</b>	<b>31,886</b>
<b>Current assets</b>			
Debtors	15	329,677	67,611
Cash at bank and in hand		314,496	497,582
		<b>644,173</b>	<b>565,193</b>
<b>Creditors:</b> amounts falling due within one year	16	<b>(181,614)</b>	<b>(273,745)</b>
<b>Net current assets</b>		<b>462,559</b>	<b>291,448</b>
<b>Net assets</b>		<b>492,946</b>	<b>323,334</b>
<b>Charity Funds</b>			
Restricted funds	17	5,242	5,242
Unrestricted funds	17	487,704	318,092
<b>Total funds</b>		<b>492,946</b>	<b>323,334</b>

The financial statements were approved by the Trustees on *6 July 2017* and signed on their behalf, by:

  
 .....  
 Mr R Edwards FCA, Chairman

  
 .....  
 Mr S'D Boley ACA, Treasurer

The notes on pages 17 to 30 form part of these financial statements.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Consolidated cash flow statement**  
**for the year ended 28 February 2017**

---

	<b>Note</b>	<b>2017</b> <b>£</b>	<b>2016</b> <b>£</b>
<b>Cash flows from operating activities</b>			
Net cash provided by operating activities	19	<u>168,000</u>	<u>202,997</u>
<b>Cash flows from investing activities:</b>			
Purchase of tangible fixed assets		<u>(7,372)</u>	<u>(6,644)</u>
<b>Net cash used in investing activities</b>		<u>(7,372)</u>	<u>(6,644)</u>
<b>Change in cash and cash equivalents in the year</b>		<b>160,628</b>	<b>196,353</b>
Cash and cash equivalents brought forward		<u>610,149</u>	<u>413,796</u>
<b>Cash and cash equivalents carried forward</b>	20	<u><u>770,777</u></u>	<u><u>610,149</u></u>

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Notes to the financial statements**  
**for the year ended 28 February 2017**

---

**1. Accounting policies**

**1.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK) meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The statement of financial activities (SOFA) and balance sheet consolidate the financial statements of the charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the charity alone as permitted by section 408 of the Companies Act 2006.

**1.2 Reconciliation with previous Generally Accepted Accounting Practice**

In preparing these accounts, the Trustees have considered whether in applying the accounting policies required by FRS 102 and the Charities SORP FRS 102 the restatement of comparative items was required.

No restatements were required.

**1.3 Company status**

The charity is a company limited by guarantee, registered in the UK. The members of the company are the Trustees named on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

The Charity's registered number and registered office address can be found on the Company Information page.

**1.4 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Notes to the financial statements**  
**for the year ended 28 February 2017**

---

**1. Accounting policies (continued)**

**1.5 Income**

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Gifts in kind donated for distribution are included at valuation and recognised as income when they are distributed to the projects. Gifts donated for resale are included as income when they are sold. Donated facilities are included at the value to the charity where this can be quantified and a third party is bearing the cost. No amounts are included in the financial statements for services donated by volunteers.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of the Friends is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Notes to the financial statements**  
**for the year ended 28 February 2017**

---

**1. Accounting policies (continued)**

**1.6 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity.

Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

**1.7 Basis of consolidation**

The financial statements consolidate the accounts of Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK) and all of its subsidiary undertakings ('subsidiaries').

The charity has taken advantage of the exemption contained within 408 of the Companies Act 2006 not to present its own income and expenditure account.

The income and expenditure account for the year dealt with in the accounts of the charity was £143,990 (2016 - £34,630).

**1.8 Tangible fixed assets and depreciation**

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Office equipment	-	15% - 33% straight line
------------------	---	-------------------------

**1.9 Investments**

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the balance sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading 'Gains/(losses) on investments' in the statement of financial activities.

- (i) **Subsidiary undertakings**  
Investments in subsidiaries are valued at cost less provision for impairment.

**1.10 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Notes to the financial statements**  
**for the year ended 28 February 2017**

---

**1. Accounting policies (continued)**

**1.11 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**1.12 Cash at bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**1.13 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

**1.14 Financial instruments**

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**1.15 Pensions**

The charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the charity to the fund in respect of the year.

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

**Notes to the financial statements  
for the year ended 28 February 2017**

**2. Income from donations and legacies**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	<i>Total funds 2016 £</i>
Corporate donations	140,860	-	140,860	136,356
Legacies	6,137	-	6,137	73,966
Gift aid	12,720	-	12,720	11,823
Public donations	-	-	-	334
	<u>159,716</u>	<u>-</u>	<u>159,716</u>	<u>222,479</u>

**3. Charitable activities**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	<i>Total funds 2016 £</i>
Other funding	150,427	-	150,427	111,275
Literature and misc sales	31	-	31	119
	<u>150,458</u>	<u>-</u>	<u>150,458</u>	<u>111,394</u>

**4. Trading Income**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	<i>Total funds 2016 £</i>
Turnover	752,601	-	752,601	433,337
	<u>752,601</u>	<u>-</u>	<u>752,601</u>	<u>433,337</u>

**5. Other income**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	<i>Total funds 2016 £</i>
Sponsorship and other income	110,985	-	110,985	21,583
	<u>110,985</u>	<u>-</u>	<u>110,985</u>	<u>21,583</u>

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

**Notes to the financial statements  
for the year ended 28 February 2017**

**6. Investment income**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
Dividend received	716	-	716	701
Interest received	3,084	-	3,084	3,561
	<u>3,800</u>	<u>-</u>	<u>3,800</u>	<u>4,262</u>

**7. Raising funds**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
Staff costs	54,892	-	54,892	71,872
Other fund raising costs	30,757	-	30,757	42,282
Total	<u>85,649</u>	<u>-</u>	<u>85,649</u>	<u>114,154</u>

**8. Trading costs**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
Staff costs	76,673	-	76,673	36,028
Direct costs	292,895	-	292,895	242,655
Administrative expenses	53,187	-	53,187	37,061
Total	<u>422,755</u>	<u>-</u>	<u>422,755</u>	<u>315,744</u>

**9. Charitable activities**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
Awareness, education and patient support	493,206	-	493,206	389,173



**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

**Notes to the financial statements  
for the year ended 28 February 2017**

**10. Governance costs**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
Audit and accountancy fees	<u>8,000</u>	<u>-</u>	<u>8,000</u>	<u>7,260</u>

**11. Net incoming resources/(resources expended)**

This is stated after charging:

	2017 £	2016 £
Depreciation of tangible fixed assets: - owned by the charitable group	10,533	11,135
Auditors' remuneration - audit	<u>8,000</u>	<u>7,260</u>

During the year, no Trustees received any remuneration (2016 - £NIL).  
During the year, no Trustees received any benefits in kind (2016 - £NIL).

**12. Staff costs**

	2017 £	2016 £
Wages and salaries	305,230	244,394
Social security costs	26,074	22,658
Other pension costs	9,041	6,671
	<u>340,345</u>	<u>273,723</u>

The average number of full-time equivalent employees (including casual and part time staff) during the year was made up as follows:

	2017 No.	2016 No.
Charitable operations	8	6
Management and central services	1	1
Consultancy	1	1
	<u>10</u>	<u>8</u>

No employee received remuneration amounting to more than £60,000 in either year (2016: none).

Key management personnel received remuneration totalling £100,027 in the year (2016: £83,136).

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

**Notes to the financial statements  
for the year ended 28 February 2017**

**13. Tangible fixed assets**

<b>Group</b>	<b>Office equipment £</b>
<b>Cost</b>	
At 1 March 2016	76,802
Additions	7,372
Disposals	(54,987)
	29,187
At 28 February 2017	29,187
<b>Depreciation</b>	
At 1 March 2016	58,475
Charge for the year	10,533
On disposals	(54,987)
	14,021
At 28 February 2017	14,021
<b>Net book value</b>	
At 28 February 2017	15,166
<i>At 29 February 2016</i>	18,327
	<b>Office equipment £</b>
<b>Charity</b>	
<b>Cost</b>	
At 1 March 2016	76,802
Additions	7,372
Disposals	(54,987)
	29,187
At 28 February 2017	29,187
<b>Depreciation</b>	
At 1 March 2016	58,475
Charge for the year	10,533
On disposals	(54,987)
	14,021
At 28 February 2017	14,021
<b>Net book value</b>	
At 28 February 2017	15,166
<i>At 29 February 2016</i>	18,327

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

**Notes to the financial statements  
for the year ended 28 February 2017**

**14. Fixed asset investments**

	<b>Listed securities £</b>
<b>Group</b>	
<b>Market value</b>	
At 1 March 2016	13,557
Revaluations	1,662
	15,219
At 28 February 2017	15,219

**Group investments at market value comprise:**

	<b>28 February 2017 £</b>	<i>29 February 2016 £</i>
Listed investments	15,219	13,557

All the fixed asset investments are held in the UK

	<b>Listed securities £</b>	<b>Sub total carried forward £</b>
<b>Charity</b>		
<b>Market value</b>		
At 1 March 2016	13,557	13,557
Revaluations	1,662	1,662
	15,219	15,219
At 28 February 2017	15,219	15,219

	<b>Sub total brought forward £</b>	<b>Shares in group undertakings £</b>	<b>Total £</b>
<b>Charity</b>			
<b>Market value</b>			
At 1 March 2016	13,557	2	13,559
Revaluations	1,662	-	1,662
	15,219	2	15,221
At 28 February 2017	15,219	2	15,221

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

**Notes to the financial statements  
for the year ended 28 February 2017**

**14. Fixed asset investments (continued)**

Charity investments at market value comprise:

	<b>28 February 2017</b>	<i>29 February 2016</i>
	£	£
Listed investments	15,219	13,557
Investment in subsidiary	2	2
<b>Total</b>	<b>15,221</b>	<b>13,559</b>

All the fixed asset investments are held in the UK.

**15. Debtors**

	<u>Group</u>		<u>Charity</u>	
	<b>28 February 2017</b>	<i>29 February 2016</i>	<b>28 February 2017</b>	<i>29 February 2016</i>
	£	£	£	£
Trade debtors	222,402	122,797	922	485
Amounts owed by group undertakings	-	-	305,536	-
Prepayments and accrued income	68,283	107,964	23,219	67,126
	<b>290,685</b>	<b>230,761</b>	<b>329,677</b>	<b>67,611</b>

**16. Creditors:  
Amounts falling due within one year**

	<u>Group</u>		<u>Charity</u>	
	<b>28 February 2017</b>	<i>29 February 2016</i>	<b>28 February 2017</b>	<i>29 February 2016</i>
	£	£	£	£
Trade creditors	113,879	108,392	43,414	42,572
Amounts owed to group undertakings	-	-	-	15,979
Other taxation and social security	84,718	32,605	7,838	6,256
FH Europe	86,852	166,917	86,852	166,917
Other creditors	1,897	3,432	1,897	3,432
Accruals and deferred income	337,069	263,628	41,613	38,589
	<b>624,415</b>	<b>574,974</b>	<b>181,614</b>	<b>273,745</b>

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

**Notes to the financial statements  
for the year ended 28 February 2017**

**17. Statement of funds**

	Brought Forward £	Income £	Expenditur e £	Gains/ (Losses) £	Carried Forward £
<b>Unrestricted funds</b>					
General Funds - all funds	292,578	1,151,938	(1,009,610)	1,662	436,568
Other General funds	-	25,622	-	-	25,622
	<u>292,578</u>	<u>1,177,560</u>	<u>(1,009,610)</u>	<u>1,662</u>	<u>462,190</u>
<b>Restricted funds</b>					
The Audrey & Eric Brent Foundation	5,242	-	-	-	5,242
Total of funds	<u>297,820</u>	<u>1,177,560</u>	<u>(1,009,610)</u>	<u>1,662</u>	<u>467,432</u>

**Name of fund**

The Audrey & Eric Brent Foundation

**Description, nature and purpose of fund**

The family has given permission for the fund to be used to support HEART UK's new website development.

**Summary of funds**

	Brought Forward £	Income £	Expenditur e £	Gains/ (Losses) £	Carried Forward £
General funds	292,578	1,177,560	(1,009,610)	1,662	462,190
Restricted funds	5,242	-	-	-	5,242
	<u>297,820</u>	<u>1,177,560</u>	<u>(1,009,610)</u>	<u>1,662</u>	<u>467,432</u>

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

**Notes to the financial statements  
for the year ended 28 February 2017**

**18. Analysis of net assets between funds**

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
Tangible fixed assets	15,166	-	15,166	18,327
Fixed asset investments	15,219	-	15,219	13,557
Current assets	1,056,219	5,242	1,061,461	840,911
Creditors due within one year	(624,414)	-	(624,414)	(574,975)
	<u>462,190</u>	<u>5,242</u>	<u>467,432</u>	<u>297,820</u>

**19. Reconciliation of net movement in funds to net cash flow from operating activities**

	2017 £	2016 £
Net income/(expenditure) for the year (as per statement of financial activities)	169,612	(34,630)
<b>Adjustment for:</b>		
Depreciation charges	10,533	11,135
(Losses)/gains on investments	(1,662)	1,354
Increase in debtors	(59,924)	(51,857)
Increase in creditors	49,441	276,995
<b>Net cash provided by operating activities</b>	<u>168,000</u>	<u>202,997</u>

**20. Analysis of cash and cash equivalents**

	2017 £	2016 £
Cash in hand	770,777	610,149
<b>Total</b>	<u>770,777</u>	<u>610,149</u>

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
(A company limited by guarantee)

---

**Notes to the financial statements  
for the year ended 28 February 2017**

---

**21. Pension commitments**

The group operates a defined contributions pension scheme. The pension cost charge in the year represents contributions payable by the group and amounted to £646 (2016 - £31).

**22. Operating lease commitments**

At 28 February 2017 the total of the group's future minimum lease payments under non-cancellable operating leases was:

	<b>28 February 2017</b>	<i>29 February 2016</i>
	£	£
<b>Group</b>		
<b>Amounts payable:</b>		
Within 1 year	<b>13,738</b>	976
Between 1 and 5 years	<b>15,700</b>	-
Total	<b>29,438</b>	976

At 28 February 2017 the charity had annual commitments under non-cancellable operating leases as follows:

**Charity**

**Amounts payable:**

Within 1 year	<b>13,738</b>	-
Between 1 and 5 years	<b>15,700</b>	-
Total	<b>29,438</b>	-

**23. Related party transactions**

Some of the Trustees hold positions within organisations with which HEART UK has links. Some of those organisations may make donations to, or seek product approval licenses from the charity or its trading subsidiary. The charity has a conflict of interest policy in place to ensure that potential conflicts are identified and dealt with appropriately. The company has taken advantage of the exemptions allowed by FRS 102, not to disclose transactions with related party undertakings which are wholly owned by the group.

Mr M Crozier is a publisher and operates under the name Crozier Associates. Crozier Associates were appointed to produce our membership magazine, Cholesterol News. During the year £8,111 (2016: £11,349) was paid to Crozier Associates for these services. The balance due at the year end was nil (2016: £4,049).

The charity provides administration and other services to FH Europe, a registered charitable incorporated organisation with links to patient organisations across Europe. The charity holds and administers funds on behalf of FH Europe whilst the latter arranges its own bank account. Since the agreement has been in place, the charity has received total funds of £218,000 on behalf of FH Europe. Of those funds, £131,148 has covered recharged costs with £99,232 recognised during 2016/17 under Other Income.

---

**Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK)**  
**(A company limited by guarantee)**

---

**Notes to the financial statements**  
**for the year ended 28 February 2017**

---

**23. Related party transactions (continued)**

At the year end, £86,852 (2016: £166,917) was therefore owed to FH Europe and is included within creditors.

**24. First time adoption of FRS 102**

It is the first year that the charity has presented its financial statements under SORP 2015 and FRS 102. The following disclosures are required in the year of transition. The last financial statements prepared under previous UK GAAP were for the year ended 29 February 2016 and the date of transition to FRS 102 and SORP 2015 was therefore 1 March 2015. The policies applied under the charity's previous accounting framework are not materially different to FRS 102 and have not impacted on funds or net income/expenditure.

**25. Principal subsidiaries**

<b>Company name</b>	<b>Country</b>	<b>Percentage Shareholding</b>	<b>Description</b>
HEART UK Trading Company Limited	UK	100	Trading subsidiary